期刊
LUNG INDIA
卷 32, 期 1, 页码 50-52出版社
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/0970-2113.148451
关键词
Interstitial lung disease; pirfenidone; systemic sclerosis
Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associated ILD who showed a subjective as well as objective improvement in lung function with pirfenidone.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据